PROQR THERAPEUTICS Debt To Equity vs. EBITDA

0PQ Stock  EUR 3.40  0.01  0.29%   
Based on PROQR THERAPEUTICS's profitability indicators, PROQR THERAPEUTICS EO 04 may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess PROQR THERAPEUTICS's ability to earn profits and add value for shareholders.
For PROQR THERAPEUTICS profitability analysis, we use financial ratios and fundamental drivers that measure the ability of PROQR THERAPEUTICS to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well PROQR THERAPEUTICS EO 04 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between PROQR THERAPEUTICS's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of PROQR THERAPEUTICS EO 04 over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between PROQR THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if PROQR THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PROQR THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

PROQR THERAPEUTICS EBITDA vs. Debt To Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining PROQR THERAPEUTICS's current stock value. Our valuation model uses many indicators to compare PROQR THERAPEUTICS value to that of its competitors to determine the firm's financial worth.
PROQR THERAPEUTICS EO 04 is number one stock in debt to equity category among its peers. It is rated third in ebitda category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PROQR THERAPEUTICS's earnings, one of the primary drivers of an investment's value.

PROQR EBITDA vs. Debt To Equity

Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

PROQR THERAPEUTICS

D/E

 = 

Total Debt

Total Equity

 = 
0.61 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

PROQR THERAPEUTICS

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(66 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

PROQR EBITDA Comparison

PROQR THERAPEUTICS is currently under evaluation in ebitda category among its peers.

PROQR THERAPEUTICS Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in PROQR THERAPEUTICS, profitability is also one of the essential criteria for including it into their portfolios because, without profit, PROQR THERAPEUTICS will eventually generate negative long term returns. The profitability progress is the general direction of PROQR THERAPEUTICS's change in net profit over the period of time. It can combine multiple indicators of PROQR THERAPEUTICS, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. PROQR THERAPEUTICS is traded on Frankfurt Stock Exchange in Germany.

PROQR Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on PROQR THERAPEUTICS. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of PROQR THERAPEUTICS position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the PROQR THERAPEUTICS's important profitability drivers and their relationship over time.

Use PROQR THERAPEUTICS in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PROQR THERAPEUTICS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PROQR THERAPEUTICS will appreciate offsetting losses from the drop in the long position's value.

PROQR THERAPEUTICS Pair Trading

PROQR THERAPEUTICS EO 04 Pair Trading Analysis

The ability to find closely correlated positions to PROQR THERAPEUTICS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PROQR THERAPEUTICS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PROQR THERAPEUTICS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PROQR THERAPEUTICS EO 04 to buy it.
The correlation of PROQR THERAPEUTICS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PROQR THERAPEUTICS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PROQR THERAPEUTICS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PROQR THERAPEUTICS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your PROQR THERAPEUTICS position

In addition to having PROQR THERAPEUTICS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Video Games Thematic Idea Now

Video Games
Video Games Theme
Companies that are involved in the building and marketing of video games or gaming software. The Video Games theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Video Games Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in PROQR Stock

To fully project PROQR THERAPEUTICS's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of PROQR THERAPEUTICS at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include PROQR THERAPEUTICS's income statement, its balance sheet, and the statement of cash flows.
Potential PROQR THERAPEUTICS investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although PROQR THERAPEUTICS investors may work on each financial statement separately, they are all related. The changes in PROQR THERAPEUTICS's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on PROQR THERAPEUTICS's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.